Technical Analysis for 0KF3 - Palatin Technologies Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.86 | 9.41% | 0.16 |
Earnings due: May 14
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Slingshot Bearish | Bearish Swing Setup | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Gilligan's Island Buy Setup | Bullish Swing Setup | 9.41% | |
| Narrow Range Bar | Range Contraction | 9.41% | |
| Wide Bands | Range Expansion | 9.41% | |
| Down 3 Days in a Row | Weakness | 9.41% |
| Alert | Time |
|---|---|
| Non-ADX 1,2,3,4 Bearish Retracement Entry | 9 days ago |
| Fell Below Previous Day's Low | 9 days ago |
| Down 3% | 9 days ago |
| Down 2% | 9 days ago |
| Down 1% | 9 days ago |
Get this analysis on your stocks daily!
Palatin Technologies Inc. Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Classification
Keywords: Biopharmaceutical Diseases Ulcerative Colitis Inflammatory Bowel Disease G Protein Coupled Receptors Inflammatory Bowel Diseases Treatment Of Inflammatory Bowel Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.7989 |
| 52 Week Low | 1.458 |
| Average Volume | 2,281 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 2.36 |
| 20-Day Moving Average | 2.24 |
| 10-Day Moving Average | 1.85 |
| Average True Range | 0.22 |
| RSI (14) | 27.54 |
| ADX | 13.83 |
| +DI | 36.93 |
| -DI | 43.63 |
| Chandelier Exit (Long, 3 ATRs) | 3.54 |
| Chandelier Exit (Short, 3 ATRs) | 2.35 |
| Upper Bollinger Bands | 3.42 |
| Lower Bollinger Band | 1.06 |
| Percent B (%b) | 0.34 |
| BandWidth | 105.63 |
| MACD Line | -0.22 |
| MACD Signal Line | -0.18 |
| MACD Histogram | -0.047 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.92 | ||||
| Resistance 3 (R3) | 1.91 | 1.89 | 1.91 | ||
| Resistance 2 (R2) | 1.89 | 1.87 | 1.89 | 1.91 | |
| Resistance 1 (R1) | 1.87 | 1.86 | 1.88 | 1.88 | 1.90 |
| Pivot Point | 1.85 | 1.85 | 1.85 | 1.85 | 1.85 |
| Support 1 (S1) | 1.83 | 1.83 | 1.84 | 1.84 | 1.82 |
| Support 2 (S2) | 1.81 | 1.82 | 1.81 | 1.81 | |
| Support 3 (S3) | 1.79 | 1.81 | 1.81 | ||
| Support 4 (S4) | 1.80 |
